Results from an early-stage clinical trial found encouraging outcomes in newly diagnosed pancreatic cancer that had spread to distant organs.

The CXCR4-CXCL12 axis drives immune exclusion and immunosuppression in pancreatic cancer. Here, the authors report a single-arm phase 2 study of metastatic pancreatic cancer evaluating motixafortide (...

Discover how single-cell CXCR4 biomarker stratification revealed hidden clinical utility for Motixafortide in AML patients, overcoming the limitations of bulk sequencing.

AbstractBackground. The MORPHEUS platform comprised multiple open-label, randomized, phase Ib/II trials to identify early signals with different treatment

Motixafortide is a high-affinity CXCR4 antagonist designed for molecular mechanism research, in vitro signal transduction analysis, and cell migration studies. It selectively inhibits the C-X-C chemokine receptor type 4 (CXCR4), making it an essential tool for probing chemokine receptor-mediated cellular localization and signaling pathways (IC₅₀ ~0.4–4.5 nM).

BioLineRx Ltd. announces its Q3 2025 financial results, alongside an update on corporate initiatives, including joint venture developments.

Motixafortide is a potent and selective CXCR4 antagonist used in tumor microenvironment, stem cell mobilization, and immuno-oncology research. GMP-quality peptide with ≥99.88% purity. For laboratory use only.（For wholesale prices, other specifications and uses, please consult our staff）

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from t...

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from t...

BioLineRx Ltd. reveals promising data from its combination therapy trial for pancreatic cancer, showcasing a significant advance in treatment options for this challenging disease.

- 4 of 11 PDAC patients in the pilot phase remained progression free at over one year - Poster presentation on Saturday, May 31st TEL AVIV, Israel, May 30, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing...

Reported Friday, May 30 - 7:05am EDT (TheFly subscription required to read more.)

Introduction Motixafortide, a CXCR4 antagonist, and filgrastim, a granulocyte colony-stimulating factor, have shown significant potential in enhancing hematopoietic stem cell mobilization and improv...

ABSTRACT Introduction Motixafortide, a CXCR4 antagonist, and filgrastim, a granulocyte colony-stimulating factor, have shown significant potential in enhancing hematopoietic stem cell mobilization and improving cancer treatment outcomes when used in combination. However, critical challenges persist due to the absence of analytical methods and the necessity for reliable quantification of both drugs in biological matrices. This research aims to address these gaps by developing and validating a liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of motixafortide and filgrastim in rat plasma. Experiment An isocratic mobile phase with acetonitrile and buffer was employed for separation, following protein precipitation with acetonitrile, using a C18 Waters X-Terra RP-18 column (150x4.6 mm,3.5 μm). Liquid chromatography–tandem mass spectrometry with an internal standard employs multiple reaction monitoring in electrospray ionization (positive ion mode) to monitor the transitions. The method was validated according to USFDA guidelines, assessing parameters such as selectivity, matrix effect, linearity, precision, accuracy, lower limit of quantification, and stability. Results This method was successfully applied in pharmacokinetic studies, ensuring reliable and accurate quantification of co-administered motixafortide and filgrastim. These findings significantly contribute to optimizing therapeutic protocols and enhancing treatment outcomes for cancer patients.

BioLineRx has reported its Q1 2025 financial results, showcasing significant advancements in drug development and corporate strategies in oncology and rare diseases.

- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. for APHEXDA® (motixafortide) with $10 million upfront payment, up to $87 million in...